Stock Track | Aurinia Pharmaceuticals Plummets 5.13% Intraday as 2026 Revenue Guidance Misses Estimates

Stock Track
02/27

Aurinia Pharmaceuticals (AUPH) stock plummeted 5.13% during Thursday's intraday trading session, reversing earlier gains.

The sharp decline came after the company reported strong fourth-quarter results but issued full-year 2026 revenue guidance that fell short of analyst expectations. Aurinia posted Q4 earnings of $1.53 per diluted share, significantly beating the FactSet consensus estimate of $0.26, while revenue of $77.1 million also exceeded the $74.7 million forecast.

However, the company's outlook for 2026 total revenue in the range of $315 million to $325 million came in below the analyst consensus estimate of $326.8 million, prompting a sell-off as investors reacted to the guidance miss.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10